Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer

被引:86
作者
Morgan, Richard [1 ]
Boxall, Angela [1 ]
Bhatt, Aagna [1 ]
Bailey, Michael [2 ]
Hindley, Richard [5 ]
Langley, Stephen [3 ]
Whitaker, Hayley C. [4 ]
Neal, David E. [4 ]
Ismail, Mohammed [1 ]
Whitaker, Hamish [1 ]
Annels, Nicola [1 ]
Michael, Agnieszka [1 ]
Pandha, Hardev [1 ]
机构
[1] Univ Surrey, Fac Hlth & Med Sci, Postgrad Med Sch, Guildford GU2 7WG, Surrey, England
[2] Univ London, London, England
[3] Royal Surrey Cty Hosp, Guildford, Surrey, England
[4] CRUK Cambridge Res Inst, Urooncol Res Grp, Cambridge, England
[5] Basingstoke Hosp, Basingstoke, Hants, England
关键词
ANTIGEN LEVEL; CELL-DEATH; HOX GENES; CARCINOMA; MEN; SECRETION; BIOPSY; MARKER; TRIAL; RATES;
D O I
10.1158/1078-0432.CCR-10-2410
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Prostate cancer (PC) is the second most common cause of cancer related death in men. A number of key limitations with prostate specific antigen (PSA), currently the standard detection test, has justified evaluation of new biomarkers. We have assessed the diagnostic potential of Engrailed-2 (EN2) protein, a homeodomain-containing transcription factor expressed in PC cell lines and secreted into the urine by PC in men. Experimental Design: EN2 expression in PC cell lines and prostate cancer tissue was determined by semi-quantative RT-PCR and immunohistochemistry. First pass urine [without prior digital rectal examination (DRE)] was collected from men presenting with urinary symptoms (referred to exclude/confirm the presence of prostate cancer) and from controls. EN2 protein was measured by ELISA in urine from men with PC (n = 82) and controls (n = 102). Results: EN2 was expressed and secreted by PC cell lines and PC tissue but not by normal prostate tissue or stroma. The presence of EN2 in urine was highly predictive of PC, with a sensitivity of 66% and a specificity of 88.2%, without requirement for DRE. There was no correlation with PSA levels. These results were confirmed independently by a second academic center. Conclusions: Urinary EN2 is a highly specific and sensitive candidate biomarker of prostate cancer. A larger multicenter study to further evaluate the diagnostic potential of EN2 is justified. Clin Cancer Res; 17(5); 1090-8. (C)2011 AACR.
引用
收藏
页码:1090 / 1098
页数:9
相关论文
共 36 条
[1]   Mortality Results from a Randomized Prostate-Cancer Screening Trial [J].
Andriole, Gerald L. ;
Grubb, Robert L., III ;
Buys, Saundra S. ;
Chia, David ;
Church, Timothy R. ;
Fouad, Mona N. ;
Gelmann, Edward P. ;
Kvale, Paul A. ;
Reding, Douglas J. ;
Weissfeld, Joel L. ;
Yokochi, Lance A. ;
Crawford, E. David ;
O'Brien, Barbara ;
Clapp, Jonathan D. ;
Rathmell, Joshua M. ;
Riley, Thomas L. ;
Hayes, Richard B. ;
Kramer, Barnett S. ;
Izmirlian, Grant ;
Miller, Anthony B. ;
Pinsky, Paul F. ;
Prorok, Philip C. ;
Gohagan, John K. ;
Berg, Christine D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) :1310-1319
[2]   Individualized screening interval for prostate cancer based on prostate-specific antigen level - Results of a prospective, randomized, population-based study [J].
Aus, G ;
Damber, JE ;
Khatami, A ;
Lilja, H ;
Stranne, J ;
Hugosson, J .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (16) :1857-1861
[3]   BIOMARKERS FOR PROSTATE CANCER DETECTION AND, PROGRESSION: BEYOND PROSTATE-SPECIFIC ANTIGEN [J].
Berney, Daniel M. .
DRUG NEWS & PERSPECTIVES, 2010, 23 (03) :185-194
[4]   SCREENING FOR PROSTATIC-CARCINOMA WITH PROSTATE SPECIFIC ANTIGEN [J].
BRAWER, MK ;
CHETNER, MP ;
BEATIE, J ;
BUCHNER, DM ;
VESSELLA, RL ;
LANGE, PH .
JOURNAL OF UROLOGY, 1992, 147 (03) :841-845
[5]   Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL [J].
Canby-Hagino, Edith ;
Hernandez, Javier ;
Brand, Timothy C. ;
Troyer, Dean A. ;
Higgons, Betsy ;
Ankerst, Donna Pauler ;
Thompson, Ian M. ;
Leach, Robin J. ;
Parekh, Dipen J. .
UROLOGY, 2007, 70 (04) :748-752
[6]   MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER [J].
CATALONA, WJ ;
SMITH, DS ;
RATLIFF, TL ;
DODDS, KM ;
COPLEN, DE ;
YUAN, JJJ ;
PETROS, JA ;
ANDRIOLE, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1156-1161
[7]   Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells [J].
Daniels, T. R. ;
Neacato, I. I. ;
Rodriguez, J. A. ;
Pandha, H. S. ;
Morgan, R. ;
Penichet, M. L. .
LEUKEMIA, 2010, 24 (09) :1555-1565
[8]   Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience [J].
DiBlasio, Christopher J. ;
Malcolm, John B. ;
Hammett, Jessica ;
Wan, Jim Y. ;
Aleman, Michael A. ;
Patterson, Anthony L. ;
Wake, Robert W. ;
Derweesh, Ithaar H. .
BJU INTERNATIONAL, 2009, 104 (09) :1208-1214
[9]   Role of tumor markers in patients with solid cancers: A critical review [J].
Duffy, Michael J. .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2007, 18 (03) :175-184
[10]   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917